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Background: Resistant HCV populations may pre-exist in patients before NS3
protease inhibitor therapy and would likely be selected under specific antiviral
pressure. The higher prevalence and lower rate of response to treatment associated
with HCV genotype 1 infections has led to drug discovery efforts being focused
primarily on enzymes produced by this genotype. Protease inhibitors may also be
useful for non-genotype-1-infected patients, notably for non-responders.Methods: We
investigated the prevalence of dominant resistance mutations and polymorphism in
298 HCV protease-inhibitor-naive patients infected with HCV genotypes 1, 2, 3, 4 or
5. Genotype-specific NS3 primers were designed to amplify and sequence the NS3
protease gene. Results: None of the 233 analysed sequences contained major
telaprevir (TVR) or boceprevir (BOC) resistance mutations (R155K/T/M, A156S/V/T
and V170A). Some substitutions (V36L, T54S, Q80K/R, D168Q and V170T) linked to
low or moderate decreases in HCV sensitivity to protease inhibitors were prevalent
according to genotype (between 2% and 100%). Other than genotype signature
mutations at positions 36, 80 and 168, the most frequent substitution was T54S (4
genotype 1 and 2 genotype 4 sequences). All genotype 2–5 sequences had the non-
genotype-1 signature V36L mutation known to confer low-level resistance to both
TVR and BOC. Conclusions: We have developed an HCV protease NS3 inhibitor
resistance genotyping tool suitable for use with HCV genotypes 1–5. Polymorphism
data is valuable for interpreting genotypic resistance profiles in cases of failure of
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